Table 6.

Progression‐free survival (PFS) in the four different groups according to the development of macrocytosis and hypothyroidism for sunitinib‐treated (n = 42 with available data)

GROUP	Macrocytosis	Hypothyroidism	n = 42	PFS (median)	95% CI	P‐value
1	Yes	Yes	13	25	20–32	<0.0001
2	Yes	No	13	11	6–28
3	No	Yes	6	10.5	3–18
4	No	No	10	3	1–6